# A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma

> **NCT02738489** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Advanced Melanoma

## Interventions

- **BIOLOGICAL:** SHR-1210

## Key facts

- **NCT ID:** NCT02738489
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-13
- **Primary completion:** 2020-01-08
- **Final completion:** 2020-01-08
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02738489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02738489, "A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02738489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*